A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

CHU de Liège, Liège

UNC Hospitals - UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Clinica Universidad de Navarra-Oncology Service, Madrid

The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro - Oncologia, Madrid

Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona, Pamplona

Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale, Bordeaux

Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale, Saint-Herblain

Centre Oscar Lambret - Service Oncologie, Lille

The University of Chicago Medical Center - Hyde Park - Hematology & Oncology, Chicago

Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), Villejuif

National University Hospital Medical Centre, Singapore

Jilin Cancer Hospital, Changchun

National Cancer Center Singapore - Oncology Department, Singapore

LinYi Cancer Hospital (Linyi Tumor Hospital), Linyi

Guangdong Provincial People's Hospital, Guangzhou

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

"START , San Antonio"

"South Texas Accelerated Research Therapeutics , START Rocky Mountain Region"

"Antwerp University Hospital , Oncology Department"

"Ghent University Hospital , Drug Research Unit Department"

"Universitair Ziekenhuis Leuven , Gasthuisberg Campus - General Medical Oncology"

"OncoCare Cancer Centre , Gleneagles Medical Centre"

Princess Margaret Cancer Centre - Oncology Department, Toronto

Hospital Universitari Vall d'Hebron- Oncology Service, Barcelona

Royal Marsden NHS Trust (Surrey), Sutton

The Christie NHS Foundation Trust - Christie Hospital, Manchester